A Randomized, Phase III Study ComparingConventional Dose Treatment Using a Combination of Lenalidomide,Bortezomib and Dexamethasone (RVD) to High-Dose Treatment withPeripheral Stem Cell Transplant in the Initial Management of Myeloma inPatients up to 65 Years of Age
||Dana Farber Cancer Institute
||Male and Female Patients
|U.S. Govt. ID:
||Ryan Shelton: 212-304-5485 / firstname.lastname@example.org
The purpose of this research study is to explore the drug combination, lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
This study is closed
Suzanne Lentzsch, MD
|Have you been diagnosed with multiple myeloma?